Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03312387 · ClinicalTrials.gov registry record · NA
Muscle, Essential Amino Acids, and eXercise in Heart Failure
A NA study, sponsored by Arizona State University.
- Terminated
- Registry status
- NA
- Development phase
- 1
- Enrollment target
NCT03312387: Clinical Trial NA study, sponsored by Arizona State University.
NCT03312387 is a NA study that was terminated before completion, run by Arizona State University. The registered enrollment target is 1 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03312387, a NA study, was terminated before completion, sponsored by Arizona State University.
- TERMINATED
- Registry status
- NA
- Development phase
- 1 participants
- Enrollment target
Study Summary
Half of heart failure patients have preserved ejection fraction (HFpEF). Like patients with reduced ejection fraction (HFrEF), HFpEF patients suffer from exercise intolerance (low VO2max), which reduces physical function, quality of life, and survival. Strikingly, there is no medication proven to increase survival for HFpEF patients. Whereas exercise intolerance in HFrEF patients is the result of cardiovascular limitations, physical dysfunction in HFpEF patients is largely the result of peripheral abnormalities in skeletal muscle. Indeed, research in HFpEF patients identified that physical function and VO2peak are directly related to leg lean mass, and drugs focused on improving cardiovascular function have failed to improve VO2peak. Unfortunately, no therapy has been identified for this population that can concurrently improve cardiovascular and muscle health. The need for improved muscle therapies is reinforced by the fact that HFpEF patients are commonly older adults who are predisposed to muscle wasting. Strategic essential amino acid (EAA) ingestion has been shown to improve the adaptive response of muscle to exercise. Therefore, the investigators will determine, in HFpEF patients, the extent to which ingesting a strategic mixture of EAAs during an acute aerobic exercise training program enhances the response to this exercise strategy.
Primary Outcome
Change in maximal Aerobic Capacity
Interventions
- DIETARY_SUPPLEMENT Placebo
- OTHER Exercise
- DIETARY_SUPPLEMENT Essential Amino Acids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2017-09-19 |
| Est. Completion | 2018-12-31 |
| Phase | NA |
Why NCT03312387 stopped before completion
NCT03312387 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03312387 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03312387 about?
NCT03312387 is a clinical study titled "Muscle, Essential Amino Acids, and eXercise in Heart Failure". Half of heart failure patients have preserved ejection fraction (HFpEF). Like patients with reduced ejection fraction (HFrEF), HFpEF patients suffer from exercise intolerance (low VO2max), which reduces physical function, quality of life, and survival. Strikingly, there is no medication proven to in...
What is the current status of trial NCT03312387?
This trial is currently terminated. It is a NA study. The enrollment target is 1 participants. The study started on 2017-09-19. Estimated completion is 2018-12-31.
What interventions are being tested in trial NCT03312387?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Exercise (OTHER), Essential Amino Acids (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03312387?
This trial is sponsored by Arizona State University, which has 187 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03312387's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI